Trapidil.a platelet-derived growth factor antagonist.has a beneficial effect onatherosclerosis and restenosis after PTCA.This study was to evaluste its clini-cal therapeutic efficacy for dislipidemia.62 consecutive pa...Trapidil.a platelet-derived growth factor antagonist.has a beneficial effect onatherosclerosis and restenosis after PTCA.This study was to evaluste its clini-cal therapeutic efficacy for dislipidemia.62 consecutive patients with primarydislipidemia were randomly divided into two groups.Group A(n=32)receivedtrapidil 300 mg daily and group B(n=30)with lovastatin 20 mg daily for 6 we-eks.After 6-week treatment,the results were showed in table 1.With trapidil,plasma TC and LDL significantly decreased by 12.5% and 11%,HDL signi-ficantly increased by 11.7%(P【0.05).The former effects were inferior to lov-astatin(P【0.001).Trapidil has a beneficial effect on lipid metabolism whichsignificantly decreased TC,LDL and increased HDL,but the effects were in-ferior to lovastatin.Table 1.Lipid and lipoprotein Valuca after Treatment(x±s)Compared with pretreatment.*P】0.05,**P【0.05.***P【0,01,****P【0.001Compared aronp A with B,a P】0.05,b P【0 05,c P【0.01,d P【0.001.展开更多
目的:探讨主动脉夹层患者血脂水平变化及其与院内死亡的相关性。方法:回顾性收集153例主动脉夹层患者临床资料,其中A型主动脉夹层(胸主动脉夹层)患者80例、B型主动脉夹层(腹主动脉夹层)患者73例,并选取体检中心50例单纯高血压患者作为对...目的:探讨主动脉夹层患者血脂水平变化及其与院内死亡的相关性。方法:回顾性收集153例主动脉夹层患者临床资料,其中A型主动脉夹层(胸主动脉夹层)患者80例、B型主动脉夹层(腹主动脉夹层)患者73例,并选取体检中心50例单纯高血压患者作为对照,比较主动脉夹层患者与高血压患者、A型主动脉夹层与B型主动脉夹层患者、主动脉夹层患者中存活者与院内死亡者之间的血脂水平,并对主动脉夹层患者存活者与院内死亡者之间有显著差异的血脂指标与院内死亡进行相关性分析。结果:主动脉夹层患者的总胆固醇(TC)水平显著高于单纯高血压患者[3.89(3.19,4.61)mmol/L vs 3.58(2.70,4.33)mmol/L],高密度脂蛋白胆固醇(HDL-C)水平[1.02(0.86,1.25)mmol/L vs 1.52(1.22,1.76)mmol/L]、HDL-C/TC比值[0.28(0.22,0.34)vs 0.45(0.31,0.67)]显著低于单纯高血压患者(P均<0.01);A型主动脉夹层患者的HDL-C/TC比值低于B型主动脉夹层患者[0.27(0.20,0.33)vs 0.30(0.24,0.36),P<0.05];主动脉夹层患者中院内死亡者的HDL-C水平显著低于存活者[0.82(0.69,1.04)mmol/L vs 1.06(0.89,1.33)mmol/L,P<0.01]。Spearman相关分析结果显示,血清HDL-C水平与主动脉夹层患者的院内死亡呈负相关(相关系数=-0.353)。结论:主动脉夹层患者存在明显的血脂代谢异常,血清HDL-C水平与主动脉夹层患者院内死亡呈负相关。展开更多
文摘Trapidil.a platelet-derived growth factor antagonist.has a beneficial effect onatherosclerosis and restenosis after PTCA.This study was to evaluste its clini-cal therapeutic efficacy for dislipidemia.62 consecutive patients with primarydislipidemia were randomly divided into two groups.Group A(n=32)receivedtrapidil 300 mg daily and group B(n=30)with lovastatin 20 mg daily for 6 we-eks.After 6-week treatment,the results were showed in table 1.With trapidil,plasma TC and LDL significantly decreased by 12.5% and 11%,HDL signi-ficantly increased by 11.7%(P【0.05).The former effects were inferior to lov-astatin(P【0.001).Trapidil has a beneficial effect on lipid metabolism whichsignificantly decreased TC,LDL and increased HDL,but the effects were in-ferior to lovastatin.Table 1.Lipid and lipoprotein Valuca after Treatment(x±s)Compared with pretreatment.*P】0.05,**P【0.05.***P【0,01,****P【0.001Compared aronp A with B,a P】0.05,b P【0 05,c P【0.01,d P【0.001.
文摘目的:探讨主动脉夹层患者血脂水平变化及其与院内死亡的相关性。方法:回顾性收集153例主动脉夹层患者临床资料,其中A型主动脉夹层(胸主动脉夹层)患者80例、B型主动脉夹层(腹主动脉夹层)患者73例,并选取体检中心50例单纯高血压患者作为对照,比较主动脉夹层患者与高血压患者、A型主动脉夹层与B型主动脉夹层患者、主动脉夹层患者中存活者与院内死亡者之间的血脂水平,并对主动脉夹层患者存活者与院内死亡者之间有显著差异的血脂指标与院内死亡进行相关性分析。结果:主动脉夹层患者的总胆固醇(TC)水平显著高于单纯高血压患者[3.89(3.19,4.61)mmol/L vs 3.58(2.70,4.33)mmol/L],高密度脂蛋白胆固醇(HDL-C)水平[1.02(0.86,1.25)mmol/L vs 1.52(1.22,1.76)mmol/L]、HDL-C/TC比值[0.28(0.22,0.34)vs 0.45(0.31,0.67)]显著低于单纯高血压患者(P均<0.01);A型主动脉夹层患者的HDL-C/TC比值低于B型主动脉夹层患者[0.27(0.20,0.33)vs 0.30(0.24,0.36),P<0.05];主动脉夹层患者中院内死亡者的HDL-C水平显著低于存活者[0.82(0.69,1.04)mmol/L vs 1.06(0.89,1.33)mmol/L,P<0.01]。Spearman相关分析结果显示,血清HDL-C水平与主动脉夹层患者的院内死亡呈负相关(相关系数=-0.353)。结论:主动脉夹层患者存在明显的血脂代谢异常,血清HDL-C水平与主动脉夹层患者院内死亡呈负相关。
